FBI LOGO TM.png
With 9.0% CAGR, Treatment-Resistant Depression Treatment Market Size Worth USD 2.83 Billion by 2029
November 04, 2022 06:39 ET | Fortune Business Insights
Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...
Nexstim Receives an
Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute
October 25, 2022 02:00 ET | Nexstim Oyj
Press release, Helsinki, 25 October 2022 at 9 AM (EEST) Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
22157.jpg
Global Depression Treatment Therapy Market Report 2022-2028: Selective Serotonin Reuptake Inhibitors (SSRIs) Hold Significant Share
October 10, 2022 06:43 ET | Research and Markets
Dublin, Oct. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...
Nexstim NBS 5+ Syste
Nexstim NBS 5+ System Continues to Generate Interest in the US
October 06, 2022 05:00 ET | Nexstim Oyj
Press release, Helsinki, 6 October 2022 at 12 PM (EEST) Nexstim NBS 5+ System Continues to Generate Interest in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs....
Solstice Academy
Pacific Solstice Offers Mental Health Program That Quickens Progress in Junior High and High School Students
September 09, 2022 09:00 ET | Pacific Solstice
MISSION VIEJO, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- "Recent national surveys of young people have shown alarming increases in the prevalence of certain mental health challenges— in 2019, one...
Nexstim Receives an
Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital
June 02, 2022 03:00 ET | Nexstim Oyj
Press release, Helsinki, 2 June 2022 at 10 AM (EEST) Nexstim Receives an NBS 5+ System Order from Seattle Children’s Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") today...
Nexstim Receives an
Nexstim Receives an NBS 5+ System Order from a US Customer
April 06, 2022 02:00 ET | Nexstim Oyj
Press release, Helsinki, 6 April 2022 at 9 AM (EEST) Nexstim Receives an NBS 5+ System Order from a US Customer Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received...
Nexstim Receives a S
Nexstim Receives a System Upgrade Order from a Customer in Finland
February 16, 2022 02:30 ET | Nexstim Oyj
Press release, Helsinki, 16 February 2022 at 9:30 AM (EET) Nexstim Receives a System Upgrade Order from a Customer in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received...
Nexstim Abp licensie
Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av neuropsykiatriska tillstånd
February 14, 2022 02:00 ET | Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors 14.2.2022 kl. 9.00 (EET) Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av...
Nexstim Plc to licen
Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders
February 14, 2022 02:00 ET | Nexstim Oyj
Company Announcement, Inside Information, Helsinki, 14 February 2022, at 9 AM (EET) Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of...